Regeneron Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast

_{//health-fitness.news-articles.net/content/2012/ .. erating-results-conference-call-and-webcast.html}
^{Published in Health and Fitness on Friday, February 10th 2012 at 13:21 GMT by Market Wire}  

Regeneron Announces February 13, 2012 as Date of Full Year 2011 Financial... -- TARRYTOWN, N.Y., Feb. 10, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about REGN

TARRYTOWN, N.Y., Feb. 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its fourth quarter and full year 2011 financial and operating results on Monday, February 13, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EST that day. The February 13, 2012 date is a change from the previously announced date of February 16, 2012.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ].  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products. A regulatory application has also been submitted to FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Phase 3 studies are in progress with EYLEA® in a third indication, with ZALTRAP® in a second indication, and with product candidate Sarilumab. Earlier-stage clinical programs are underway with nine additional product candidates. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

SOURCE Regeneron Pharmaceuticals, Inc.

RELATED LINKS
[ http://www.regeneron.com ]